Water mobility test for infants with SMA
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests how well infants with spinal muscular atrophy (SMA) can move in water. The goal is to see if gentle water exercises can help with muscle weakness and overall development.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby has a confirmed diagnosis of spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness.
- Your baby is getting the usual treatments for SMA.
- Your baby is under 12 years old and shorter than 90 cm (about 35 inches).
- Your baby is covered by a social security plan or similar health insurance.
- Your baby does not have any injuries or conditions in the spinal cord, heart, or lungs.
- Your baby is not enrolled in the French Aid in Health for Foreign People (AME) program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how consistent a fatigue test is for people with spinal muscular atrophy (SMA). It helps doctors better understand fatigue in SMA and may improve future care.
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This study looks at how children and teens with Duchenne muscular dystrophy (DMD) or spinal muscular atrophy (SMA) walk, by having them do walking tests while wearing sensors. The goal is to find better ways to track how these diseases progress and how treatments work over time, without needing blood tests or scans.
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
This study remotely tracks motor development in children with Duchenne muscular dystrophy or spinal muscular atrophy who were diagnosed at birth or before symptoms started. It aims to see if early monitoring helps improve long-term care and outcomes.
Hear when a new Infantile Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.